Green B J, Wyse D G, Duff H J, Mitchell L B, Matheson D S
Department of Internal Medicine, University of Calgary, Alberta.
Clin Invest Med. 1988 Dec;11(6):425-9.
Autoantibodies to histone and denatured DNA have been found in 80% of patients treated with procainamide. Of these 10 to 20% will eventually develop a Systemic Lupus Erythematosus-like syndrome. Although the mechanism by which procainamide exerts its effect is unknown, in vitro studies suggest that procainamide may inhibit suppressor T cell activity. We have studied the immune function of 18 patients receiving a two hour infusion of procainamide during transvenous catheter electrophysiologic studies. There was no difference between pre and post infusion samples with respect to T and B cell mitogenesis or pokeweed mitogen-induced immunoglobulin secretion. However, in seventeen of eighteen patients, there was a marked decrease in Concanavalin A-inducible suppressor cell activity. This decrease appeared to be related to the amount of procainamide infused as high dose samples showed less suppressor activity than low dose samples. Thus the data show that procainamide, when given in vivo, leads to a rapid and dose dependent decrease in suppressor cell activity.
在接受普鲁卡因胺治疗的患者中，80%发现有组蛋白和变性DNA的自身抗体。其中10%至20%最终会发展为系统性红斑狼疮样综合征。尽管普鲁卡因胺发挥作用的机制尚不清楚，但体外研究表明，普鲁卡因胺可能抑制抑制性T细胞活性。我们研究了18例在经静脉导管电生理研究期间接受两小时普鲁卡因胺输注患者的免疫功能。输注前后样本在T和B细胞有丝分裂或商陆有丝分裂原诱导的免疫球蛋白分泌方面没有差异。然而，18例患者中有17例，伴刀豆球蛋白A诱导的抑制细胞活性显著降低。这种降低似乎与输注的普鲁卡因胺量有关，因为高剂量样本的抑制活性低于低剂量样本。因此，数据表明，体内给予普鲁卡因胺会导致抑制细胞活性迅速且剂量依赖性降低。
